Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Rachel S Kerr; Sharon Love; Eva Segelov; Elaine Johnstone; Beverly Falcon; Peter Hewett; Andrew Weaver; David Church; Claire Scudder; Sarah Pearson; Patrick Julier; Francesco Pezzella; Ian Tomlinson; Enric Domingo; David J Kerr

doi:10.1016/S1470-2045(16)30172-3

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Rachel S Kerr, Sharon Love, Eva Segelov, Elaine Johnstone, Beverly Falcon, Peter Hewett, Andrew Weaver, David Church, Claire Scudder, Sarah Pearson, Patrick Julier, Francesco Pezzella, Ian Tomlinson, Enric Domingo, David J Kerr

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1543-1557
Journal	The Lancet Oncology
Volume	17
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(16)30172-3
Publication status	Published - 1 Nov 2016

Access to Document

10.1016/S1470-2045(16)30172-3

https://linkinghub.elsevier.com/retrieve/pii/S1470204516301723

Cite this

Kerr, R. S., Love, S., Segelov, E., Johnstone, E., Falcon, B., Hewett, P., Weaver, A., Church, D., Scudder, C., Pearson, S., Julier, P., Pezzella, F., Tomlinson, I., Domingo, E., & Kerr, D. J. (2016). Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. The Lancet Oncology, 17(11), 1543-1557. https://doi.org/10.1016/S1470-2045(16)30172-3

@article{5cb0b195459c40769d3125dc3373a2fc,

title = "Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial",

author = "Kerr, {Rachel S} and Sharon Love and Eva Segelov and Elaine Johnstone and Beverly Falcon and Peter Hewett and Andrew Weaver and David Church and Claire Scudder and Sarah Pearson and Patrick Julier and Francesco Pezzella and Ian Tomlinson and Enric Domingo and Kerr, {David J}",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/S1470-2045(16)30172-3",

language = "English",

volume = "17",

pages = "1543--1557",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "11",

}

Kerr, RS, Love, S, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E & Kerr, DJ 2016, 'Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial', The Lancet Oncology, vol. 17, no. 11, pp. 1543-1557. https://doi.org/10.1016/S1470-2045(16)30172-3

TY - JOUR

T1 - Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

AU - Kerr, Rachel S

AU - Love, Sharon

AU - Segelov, Eva

AU - Johnstone, Elaine

AU - Falcon, Beverly

AU - Hewett, Peter

AU - Weaver, Andrew

AU - Church, David

AU - Scudder, Claire

AU - Pearson, Sarah

AU - Julier, Patrick

AU - Pezzella, Francesco

AU - Tomlinson, Ian

AU - Domingo, Enric

AU - Kerr, David J

PY - 2016/11/1

Y1 - 2016/11/1

U2 - 10.1016/S1470-2045(16)30172-3

DO - 10.1016/S1470-2045(16)30172-3

M3 - Article

SN - 1470-2045

VL - 17

SP - 1543

EP - 1557

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 11

ER -